CSIMarket Company Name, Ticker, Industry, else..
 
Maia Biotechnology Inc   (NYSEAMER: MAIA)
 

Maia Biotechnology Inc's Customers Performance

MAIA


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
MAIA's Source of Revenues

• List of MAIA Customers




for the same period Maia Biotechnology Inc

• List of MAIA Customers





Maia Biotechnology Inc's Comment on Sales, Marketing and Customers



In the U.S. market, generic drugs are marketed through Abbreviated New Drug Applications (ANDAs), which demonstrate bioequivalence to listed drugs and permit pharmacists to substitute generics for branded prescriptions. Another regulatory pathway is the Section 505(b)(2) New Drug Application (NDA), allowing applicants to partially rely on the FDA's previous approvals or published literature for modified drug formulations, potentially reducing the need for new clinical trials. These pathways facilitate the introduction of products at lower costs and prices. The primary customers include pharmacies and patients receiving prescriptions. The market segment consists of generic drug products competing with branded or reference listed drugs, with generic versions often capturing significant sales from branded products after their introduction.





Maia Biotechnology Inc’s Comment on Sales, Marketing and Customers


In the U.S. market, generic drugs are marketed through Abbreviated New Drug Applications (ANDAs), which demonstrate bioequivalence to listed drugs and permit pharmacists to substitute generics for branded prescriptions. Another regulatory pathway is the Section 505(b)(2) New Drug Application (NDA), allowing applicants to partially rely on the FDA's previous approvals or published literature for modified drug formulations, potentially reducing the need for new clinical trials. These pathways facilitate the introduction of products at lower costs and prices. The primary customers include pharmacies and patients receiving prescriptions. The market segment consists of generic drug products competing with branded or reference listed drugs, with generic versions often capturing significant sales from branded products after their introduction.







MAIA's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Maia Biotechnology Inc 79.64 0.00 -24.25 13
SUBTOTAL 0.00 0.00 0.00 -

Sources: Maia Biotechnology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Maia Biotechnology Inc’s corporate clients.
For your research, we’ve provided 9 tables on Maia Biotechnology Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.